Dr. Azad on patient-reported outcome data from TALAPRO-2
“[It is] reassuring that in patients who had a prior novel hormonal agent, the combination of enzalutamide plus talazoparib is still effective [and] still an effective option,” says Arun Azad, MD.
In this video, Arun Azad, MBBS, PhD, shares the background and findings from the study, “Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study,” which was presented at the 2024 ASCO Genitourinary Cancers Symposium in San Francisco, California. Azad is a urologic oncologist at Peter MacCallum Cancer Centre and an associate professor at the University of Melbourne in Australia.
Video Transcript:
This abstract that we presented from TALAPRO-2 looked at the percentage of patients who actually had a prior novel hormonal therapy before they enrolled on this study. It was a relatively small percentage of patients, under 10%, most of them had prior abiraterone. This is relevant because this study was designed and started recruiting in 2018. At that stage, there was less use of novel hormonal agents for the metastatic hormone sensitive prostate cancer space. But of course, now, those drugs are widely used. So, one of the questions that physicians and patients have is, well, if I've had a prior novel hormonal agent for metastatic hormone sensitive prostate cancer, [are] the results of TALAPRO-2 relevant to that patient, where they've got metastatic castration resistant prostate cancer. It was a small subset, a small number of patients, but basically, the efficacy data suggested that the combination of enzalutamide plus talazoparib was just as effective in these patients who had prior novel hormonal therapies, which is reassuring and gives us an option in patients have had a prior novel hormonal agent. That was the overall results.
What we looked at in this abstract was the quality-of-life data, the patient reported outcome data. In the overall population who was on the study, we saw that there was improvement in key quality of life outcomes with enzalutamide plus talazoparib but in fact, that was even more apparent in these patients who'd had a prior novel hormonal therapy. [It is] reassuring that in patients who had a prior novel hormonal agent, the combination of enzalutamide plus talazoparib is still effective [and] still an effective option.
This transcription has been edited for clarity.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
